Ocumension Therapeutics, Monday announced an agreement to acquire commercialization rights of a Chinese portfolio of dry eye treatments and procedural drops of Alcon Inc. (ALC), in exchange for 16.71 percent equity stake.
Under the agreement, the ophthalmic pharmaceutical platform, would acquire outright Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and the commercialization rights in the country to Systane Ultra and AR-15512.
After a transition period, the Chinese company would also start manufacturing these acquired products, which is expected to enhance the company's position in the market.
Currently, Alcon's stock is dropping 0.59 percent, to $92.38 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.